SCHEMBL1007119

SCHEMBL1007119

O=C(O)CCCCCCCCCOCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
EPHX2 P34913 2/20 0.57
HDAC3 O15379 2/20 0.53
HDAC4 P56524 2/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC9 Q9UKV0 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53
MAPK1 P28482 1/20 0.53
ADRA1A P35348 1/20 0.53
SLC6A3 Q01959 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2871485 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL8984468 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL8984382 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL6422109 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL2867823 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL830483 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL1008067 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL5508985 1.00 MAPT (0.59) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL712393 0.98 MAPT (0.56) MAPTRXFP1EPHX2HDAC3HDAC4
SCHEMBL31482293 0.97 MAPT (0.56) MAPTRXFP1EPHX2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268606-B1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
CN-101952243-B 4-dimethylaminobutyric acid derivatives HOFFMANN LA ROCHE 2014-07-16 CN disclosed
US-8344027-B2 4-dimethylaminobutyric acid derivatives HOFFMANN-LA ROCHE INC. (US) 2013-01-01 US disclosed
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES ANDJELKOVIC MIRJANA (CH) 2012-11-15 US disclosed
CN-101952243-A 4-dimethylaminobutyric acid derivatives HOFFMANN LA ROCHE 2011-01-19 CN disclosed
EP-2268606-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2009132978-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-10-29 US disclosed
EP-1043982-B1 LIPASE INHIBITING POLYMERS GENZYME CORP (US) 2005-11-09 EP disclosed
US-20050085535-A1 Lipase inhibiting polymers GENZYME CORPORATION (US) 2005-04-21 US disclosed
US-6875428-B2 Lipase inhibiting polymers GENZYME CORPORATION (US) 2005-04-05 US disclosed
US-20030185789-A1 Lipase inhibiting polymers GELTEX PHARMACEUTICALS, INC. 2003-10-02 US disclosed
US-6572850-B1 Treating obesity by administering a polyether substituted with a pendant B-lactone group;reduction in fat hydrolysis and absorption GELTEX PHARMACEUTICALS, INC. 2003-06-03 US disclosed
US-6558657-B1 Synthetic polymer, carbohydrate or protein substituted with disulfide moiety that inhibits fat hydrolysis GELTEX PHARMACEUTICALS, INC. 2003-05-06 US disclosed
US-6352692-B1 POLYMERS WITH PHOSPHINO-CONTAINING FUNCTIONAL GROUP SUBSTITUENTS; ORALLY ADMINISTERING TO TREAT OBESITY AND HYPERTRIGLYCERIDEMIA GELTEX PHARMACEUTICALS, INC. 2002-03-05 US disclosed
US-6267952-B1 ORALLY ADMINISTERING TO MAMMAL A MODIFIED POLYMER WHICH FOR TREATING OBESITY GELTEX PHARMACEUTICALS, INC. 2001-07-31 US disclosed
EP-1043982-A2 LIPASE INHIBITING POLYMERS Geltex Pharmaceuticals, Inc. (US) 2000-10-18 EP disclosed
WO-1999034786-A2 LIPASE INHIBITING POLYMERS GELTEX PHARMACEUTICALS, INC. (US) 1999-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030185789-A1 Lipase inhibiting polymers PNLIP, LIPC, LPL MAPT 4393/4885RXFP1 2290/4885EPHX2 866/4885
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 MAPT 935/4885RXFP1 2945/4885EPHX2 2708/4885
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 MAPT 935/4885RXFP1 2945/4885EPHX2 2708/4885
US-20050085535-A1 Lipase inhibiting polymers PNLIP, LIPC, LPL MAPT 4393/4885RXFP1 2290/4885EPHX2 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.